This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
The new TCR (TTCR37-45) effectively killed relapsed AML cells resistant to previous targeting.
Why it matters
Understanding how leukemia cells evade immune targeting can lead to more effective therapies. This research opens new avenues for treating resistant forms of leukemia.
How the study worked
The study involved analyzing patient samples and testing T cell receptors in vitro and in a mouse model.
What this study cannot tell us
The study primarily focuses on a small number of patients and in vitro models, which may limit generalizability.
Read the original research
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Science translational medicine, 14(631), eabg8070
Citation
Lahman, Miranda C; Schmitt, Thomas M; Paulson, Kelly G; Vigneron, Nathalie; Buenrostro, Denise; Wagener, Felecia D; Voillet, Valentin; Martin, Lauren; Gottardo, Raphael; Bielas, Jason; McElrath, Julie M; Stirewalt, Derek L; Pogosova-Agadjanyan, Era L; Yeung, Cecilia C; Pierce, Robert H; Egan, Daniel N; Bar, Merav; Hendrie, Paul C; Kinsella, Sinéad; Vakil, Aesha; Butler, Jonah; Chaffee, Mary; Linton, Jonathan; McAfee, Megan S; Hunter, Daniel S; Bleakley, Marie; Rongvaux, Anthony; Van den Eynde, Benoit J; Chapuis, Aude G; Greenberg, Philip D. (2022). Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.. Science translational medicine, 14(631), eabg8070. https://doi.org/10.1126/scitranslmed.abg8070